📣 VC round data is live. Check it out!

Cambridge Cognition Valuation Multiples

Discover Cambridge Cognition's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Co-Diagnostics, Nova Eye Medical, Medclair, Integrum and more.

Cambridge Cognition Overview

About Cambridge Cognition

Cambridge Cognition Holdings PLC is a neuroscience digital health company specializing in the precise measurement of clinical outcomes in neurological disorders. Geographically, it derives majority of its revenue from the United States of America and also has a presence in the United Kingdom, European Union, and Rest of world. The company services include Neuroscience consultancy, Technical consultancy, Study design, Data analysis, Study management, Data management, and Reports and interpretation.


Founded

2012

HQ

United Kingdom

Employees

84

Financials (LTM)

Revenue: $14M
EBITDA: ($215K)

EV

$23M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cambridge Cognition Financials

Cambridge Cognition reported last 12-month revenue of $14M and negative EBITDA of ($215K).

In the same LTM period, Cambridge Cognition generated $11M in gross profit, ($215K) in EBITDA losses, and had net loss of ($2M).

Revenue (LTM)


Cambridge Cognition P&L

In the most recent fiscal year, Cambridge Cognition reported revenue of $13M and EBITDA of ($674K).

Cambridge Cognition is unprofitable as of last fiscal year, with gross margin of 75%, EBITDA margin of (5%), and net margin of (18%).

See analyst estimates for Cambridge Cognition
LTMLast FY202320242025202620272028
Revenue$14M$13M$18M$14M$13M
Gross Profit$11M$9M$15M$11M$9M
Gross Margin76%75%80%81%75%
EBITDA($215K)($674K)($4M)($730K)($891K)
EBITDA Margin(2%)(5%)(20%)(5%)(7%)
EBIT Margin(3%)(7%)(14%)(10%)(13%)
Net Profit($2M)($2M)($5M)($2M)($2M)
Net Margin(12%)(18%)(26%)(17%)(18%)

Financial data powered by Morningstar, Inc.

Cambridge Cognition Stock Performance

Cambridge Cognition has current market cap of $23M, and enterprise value of $23M.

Market Cap Evolution


Cambridge Cognition's stock price is $0.50.

Cambridge Cognition share price increased by 16.5% in the last year.

Cambridge Cognition has an EPS (earnings per share) of $-0.05.

See more trading valuation data for Cambridge Cognition
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$23M$23M0.1%0.0%-0.8%16.5%$-0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cambridge Cognition Valuation Multiples

Cambridge Cognition trades at 1.6x EV/Revenue multiple, and (106.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Cambridge Cognition

EV / Revenue (LTM)


Cambridge Cognition Financial Valuation Multiples

As of June 3, 2026, Cambridge Cognition has market cap of $23M and EV of $23M.

Cambridge Cognition has a P/E ratio of (14.2x).

LTMLast FY202320242025202620272028
EV/Revenue1.6x1.8x1.3x1.6x1.8x
EV/EBITDA(106.4x)(33.9x)(6.4x)(31.3x)(25.6x)
EV/EBIT(50.9x)(26.2x)(9.2x)(16.3x)(13.7x)
EV/Gross Profit2.2x2.4x1.6x2.0x2.4x
P/E(14.2x)(10.3x)(4.9x)(9.7x)(10.3x)
EV/FCF(86.2x)n/m(3.4x)(5.5x)n/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cambridge Cognition Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cambridge Cognition Margins & Growth Rates

Cambridge Cognition grew revenue by 24% but EBITDA decreased by 162% in the last fiscal year.

In the most recent fiscal year, Cambridge Cognition reported gross margin of 75%, EBITDA margin of (5%), and net margin of (18%).

See estimated margins and future growth rates for Cambridge Cognition

Cambridge Cognition Margins

Last FY202420252026202720282029
Gross Margin75%81%75%78%
EBITDA Margin(5%)(5%)(7%)3%
EBIT Margin(7%)(10%)(13%)1%
Net Margin(18%)(17%)(18%)(5%)
FCF Margin1%(30%)1%4%

Cambridge Cognition Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth24%(23%)(9%)24%
Gross Profit Growth29%(22%)(16%)29%
EBITDA Growth(162%)(80%)22%(147%)
EBIT Growth(115%)(44%)19%(108%)
Net Profit Growth(65%)(49%)(6%)(65%)
FCF Growth529%(38%)(102%)529%

Data powered by FactSet, Inc. and Morningstar, Inc.

Cambridge Cognition Operational KPIs

Cambridge Cognition's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Cambridge Cognition's Rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cambridge Cognition's Rule of X is 62% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cambridge Cognition
LTMLast FY202320242025202620272028
Rule of 4021%26%---
Bessemer Rule of X56%62%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue27%30%22%22%29%
G&A Expenses to Revenue33%35%45%48%35%
R&D Expenses to Revenue25%26%28%25%26%
Opex to Revenue-88%94%91%88%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cambridge Cognition Competitors

Cambridge Cognition competitors include Co-Diagnostics, Nova Eye Medical, Medclair, Integrum, Genematrix, Finemedix, Biosynex, Lifeward, Elbit Imaging and NextPlat.

Most Cambridge Cognition public comparables operate across Healthcare Software, Medical Devices, B2B SaaS, Vertical SaaS, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Co-Diagnostics27.0x27.0x(0.6x)-
Nova Eye Medical1.1x1.0x(6.6x)(14.2x)
Medclair4.2x-21.4x-
Integrum2.0x-(5.2x)-
Genematrix2.0x-(18.4x)-
Finemedix3.2x-(20.2x)-
Biosynex0.8x-60.1x-
Lifeward0.9x0.8x(1.1x)-

This data is available for Pro users. Sign up to see all Cambridge Cognition competitors and their valuation data.

Start Free Trial

Acquisitions by Cambridge Cognition

Cambridge Cognition has acquired 2 companies to date.

Last acquisition by Cambridge Cognition was on January 11th 2023. Cambridge Cognition acquired Winterlight Labs for $9M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Cambridge Cognition

Winterlight Labs
Clinpal
Description
-
Clinpal is a cloud-based eClinical platform developed by eClinicalHealth, an Ireland-headquartered firm supporting clinical trials worldwide. The patient-centric system facilitates real-time data capture from patients, sites, CRAs, and sponsors via mobile apps and web portals. Clinpal consolidates eSource biometrics, ePRO, and eConsent into a unified hub, integrating with EDC systems like Medidata Rave. Deployed in over 100 trials across oncology and rare diseases, the platform boosts retention by 20% through reminders and gamification.
HQ CountryCanadaUnited Kingdom
HQ City
-
Stirling
Deal Date11 Jan 202312 Oct 2022
Valuation$9M$2M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cambridge Cognition acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cambridge Cognition

When was Cambridge Cognition founded?Cambridge Cognition was founded in 2012.
Where is Cambridge Cognition headquartered?Cambridge Cognition is headquartered in United Kingdom.
How many employees does Cambridge Cognition have?As of today, Cambridge Cognition has over 84 employees.
Is Cambridge Cognition publicly listed?Yes, Cambridge Cognition is a public company listed on London Stock Exchange.
What is the stock symbol of Cambridge Cognition?Cambridge Cognition trades under COG ticker.
When did Cambridge Cognition go public?Cambridge Cognition went public in 2013.
Who are competitors of Cambridge Cognition?Cambridge Cognition main competitors include Co-Diagnostics, Nova Eye Medical, Medclair, Integrum, Genematrix, Finemedix, Biosynex, Lifeward, Elbit Imaging, NextPlat.
What is the current market cap of Cambridge Cognition?Cambridge Cognition's current market cap is $23M.
What is the current revenue of Cambridge Cognition?Cambridge Cognition's last 12 months revenue is $14M.
What is the current revenue growth of Cambridge Cognition?Cambridge Cognition revenue growth (NTM/LTM) is 23%.
What is the current EV/Revenue multiple of Cambridge Cognition?Current revenue multiple of Cambridge Cognition is 1.6x.
Is Cambridge Cognition profitable?No, Cambridge Cognition is not profitable.
What is the current EBITDA of Cambridge Cognition?Cambridge Cognition has negative EBITDA and is not profitable.
What is Cambridge Cognition's EBITDA margin?Cambridge Cognition's last 12 months EBITDA margin is (2%).
What is the current EV/EBITDA multiple of Cambridge Cognition?Current EBITDA multiple of Cambridge Cognition is (106.4x).
What is the current FCF of Cambridge Cognition?Cambridge Cognition's last 12 months FCF is ($265K).
What is Cambridge Cognition's FCF margin?Cambridge Cognition's last 12 months FCF margin is (2%).
What is the current EV/FCF multiple of Cambridge Cognition?Current FCF multiple of Cambridge Cognition is (86.2x).
How many companies Cambridge Cognition has acquired to date?As of June 2026, Cambridge Cognition has acquired 2 companies.
What was the largest acquisition by Cambridge Cognition?$9M acquisition of Winterlight Labs on 11th January 2023 was the largest M&A Cambridge Cognition has done to date.
What companies Cambridge Cognition acquired?Cambridge Cognition acquired Winterlight Labs and Clinpal.
In how many companies Cambridge Cognition has invested to date?Cambridge Cognition hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cambridge Cognition

Lists including Cambridge Cognition

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial